tbuckley/cabot-search huggingface dataset:
Why are hematopoietic stem cells so ‘sexy’? on a search for developmental explanation
Authors: M Z Ratajczak
Journal: Leukemia (2017)

Evidence has accumulated that normal human and murine hematopoietic stem cells express several functional pituitary and gonadal sex hormones, and that, in fact, some sex hormones, such as androgens, have been employed for many years to stimulate hematopoiesis in patients with bone marrow aplasia. Interestingly, sex hormone receptors are also expressed by leukemic cell lines and blasts. In this review, I will discuss the emerging question of why hematopoietic cells express these receptors. A tempting hypothetical explanation for this phenomenon is that hematopoietic stem cells are related to subpopulation of migrating primordial germ cells. To support of this notion, the anatomical sites of origin of primitive and definitive hematopoiesis during embryonic development are tightly connected with the migratory route of primordial germ cells: from the proximal epiblast to the extraembryonic endoderm at the bottom of the yolk sac and then back to the embryo proper via the primitive streak to the aorta-gonado-mesonephros (AGM) region on the way to the genital ridges. The migration of these cells overlaps with the emergence of primitive hematopoiesis in the blood islands at the bottom of the yolk sac, and definitive hematopoiesis that occurs in hemogenic endothelium in the embryonic dorsal aorta in AGM region.
Potential effect of hepatitis C treatment on renal, cardiovascular and metabolic extrahepatic manifestations: results from clinical trials of ombitasvir/paritaprevir/ritonavir and dasabuvir ± ribavirin
Authors: T. Tran, D. Mehta, A. Goldstein, E. Cohen, Y. Bao, Y.S. Gonzalez
Journal: Journal of Hepatology (2017)
Neoadjuvant Trials in ER+ Breast Cancer: A Tool for Acceleration of Drug Development and Discovery
Authors: Angel L. Guerrero-Zotano, Carlos L. Arteaga
Journal: Cancer Discovery (2017)

Neoadjuvant therapy trials offer an excellent strategy for drug development and discovery in breast cancer, particularly in triple-negative and HER2-overexpressing subtypes, where pathologic complete response is a good surrogate of long-term patient benefit. For estrogen receptor-positive (ER
Higher and rising prevalence and incidence of renal impairment and chronic kidney disease in chronic hepatitis B patients compared to matched non-chronic hepatitis B controls in the United States: results of a real-world analysis
Authors: M.H. Nguyen, J. Lim, I. Liou, A.B. Ozbay, J. Fraysse, N. Meyer, G. Dusheiko, S. Gordon
Journal: Journal of Hepatology (2017)
Abrupt Onset of Pustules in a Child
Authors: Mary E. Anderson, Adnan Mir, Melissa M. Mauskar
Journal: JAMA Pediatrics (2017)

An 18-month-old boy with a history of atopic dermatitis presented to the emergency department with a 2-day history of high fever and rash, which began 2 days after completing an 8-day course of clindamycin for sinusitis. What is your diagnosis?
Ledipasvir/sofosbuvir for 12 weeks is safe and effective in patients with chronic hepatitis C and hepatitis B coinfection: A phase 3 study in Taiwan
Authors: C.-J. Liu, W.-L. Chuang, I.-S. Sheen, H.-Y. Wang, C.-Y. Chen, K.-C. Tseng, T.-T. Chang, B. Massetto, J. Yang, G. Camus, F. Zhang, D.M. Brainard, J.G. McHutchison, T.-H. Hu, Y.-C. Hsu, G.-H. Lo, C.-J. Chu, J.-J. Chen, C.-Y. Peng, R.-N. Chien, P.-J. Chen
Journal: Journal of Hepatology (2017)
No increased risk of hepatocellular carcinoma recurrence in patients following interferon-free, direct acting anti-viral treatment for hepatitis C virus: a cohort study using large-scale administrative medical claims data
Authors: L.E. Telep, D. Muramoto, A. Osinusi, D.M. Brainard, K.R. Reddy, A.W. Singer, A.P. Chokkalingam
Journal: Journal of Hepatology (2017)
Abstract PR03: Molecular characterization of in vitro exhausted T cells
Authors: William Hastings, Kenzie MacIsaac, Wei Guan, Pamela Shaw, Glenn Dranoff, Z Alexander Cao
Journal: Clinical Cancer Research (2017)

Abstract In previous work we observed that restimulating human PBMCs with anti-CD3/28 beads 4 days after a primary stimulation resulted in an exhausted phenotype, as characterized by loss of T cells' ability to secrete IL-2, TNFa, and IFNg. To further characterize the molecular phenotype of these cells, we isolated CD4+ and CD8+ T cells from our exhausted and non-exhausted samples and performed Nanostring gene expression analysis. Both exhausted CD4+ and CD8+ T cells exhibited upregulation of a 25-gene exhaustion gene signature, as compared to non-exhausted control cells. In addition, a number of immunologically important molecules are modulated in the exhausted cells. For example, MIF (macrophage migration inhibitory factor) mRNA is induced in the exhausted T cells. Closer examination of MIF expression in TCGA suggests that MIF level is inversely correlated to survival in indications such as HCC and H/N cancer. Furthermore, pathway analysis of differential gene expression revealed the JAK/STAT signaling pathway as significantly upregulated in the exhausted cells. Treatment of exhausted cells with a JAK inhibitor resulted in a partial reversal of the exhausted phenotype, as shown by restored cytokine secretion. Thus we show for the first time the involvement of JAK signaling in human T cell exhaustion, which may provide rationale for combining JAK inhibitors with other immune therapies for cancer. In summary, the in vitro T cell exhaustion model system has yielded intriguing activity nodes during T cell function. Future exploration in such immunological states may identify novel therapeutic targets and combination opportunities for immuno-oncology. This abstract is also being presented as Poster B17. Citation Format: William Hastings, Kenzie MacIsaac, Wei Guan, Pamela Shaw, Glenn Dranoff, Z Alexander Cao. Molecular characterization of in vitro exhausted T cells. [abstract]. In: Proceedings of the AACR Precision Medicine Series: Targeting the Vulnerabilities of Cancer; May 16-19, 2016; Miami, FL. Philadelphia (PA): AACR; Clin Cancer Res 2017;23(1_Suppl):Abstract nr PR03.
Protective effect of quercetin treatment on HFD-induced intestinal dysbiosis and barrier dysfunction in an in vivo model of non-alcoholic fatty liver disease
Authors: D. Porras, M.V. García-Mediavilla, E. Nistal, S. Martínez-Florez, S. Pisonero-Vaquero, F. Jorquera, J.L. Olcoz, R. Jover, J. González-Gallego, S. Sánchez-Campos
Journal: Journal of Hepatology (2017)
Sofosbuvir/Ribavirin treatment in patients with genotype 2, Hepatitis C Virus infection and symptomatic mixed cryoglobulinemia: an interim analysis on safety, efficacy and impact on quality of life
Authors: G. Cerretelli, L. Gragnani, M. Monti, U. Arena, E. Fognani, L. Petraccia, E. Gianni, S. Sollima, G. Brancaccio, M. Galli, G.B. Gaeta, A.L. Zignego
Journal: Journal of Hepatology (2017)
Abundant and equipotent founder cells establish and maintain acute lymphoblastic leukaemia
Authors: A Elder, S Bomken, I Wilson, H J Blair, S Cockell, F Ponthan, K Dormon, D Pal, O Heidenreich, J Vormoor
Journal: Leukemia (2017)

High frequencies of blasts in primary acute lymphoblastic leukaemia (ALL) samples have the potential to induce leukaemia and to engraft mice. However, it is unclear how individual ALL cells each contribute to drive leukaemic development in a bulk transplant and the extent to which these blasts vary functionally. We used cellular barcoding as a fate mapping tool to track primograft ALL blasts in vivo. Our results show that high numbers of ALL founder cells contribute at similar frequencies to leukaemic propagation over serial transplants, without any clear evidence of clonal succession. These founder cells also exhibit equal capacity to home and engraft to different organs, although stochastic processes may alter the composition in restrictive niches. Our findings enhance the stochastic stem cell model of ALL by demonstrating equal functional abilities of singular ALL blasts and show that successful treatment strategies must eradicate the entire leukaemic cell population.
Cost-effectiveness of elbasvir-grazoprevir association for treating hepatitis C virus genotype 1 infection in stage 4–5 chronic kidney disease patients in France
Authors: F. Maunoury, A. Clément, E.H. Elbasha, A. Abergel, V. Di Martino, E. Thervet, L. Lévy-Bachelot, I. Durand-Zaleski
Journal: Journal of Hepatology (2017)
Minimal Residual Disease Assessment by Flow Cytometry In AML Patients at Time of Aplasia Post-Induction Is Highly Predictive of Outcome and Strongly Correlates with Molecular MRD In a Subgroup of NPM1 Positive Patients
Authors: Daniela Sauter, Katharina Ringel, Jan Braess, Wolfgang Hiddemann, Karsten Spiekermann, Marion Subklewe
Journal: Blood (2010)
Abstract B28: Discovery of 2-acetylpyridine-[N-(3-hydroxy-2-naphthoyl)]hydrazone analogs as glycine N-methyltransferase (GNMT) inducers for the treatment of hepatocellular carcinoma (HCC)
Authors: Cherng-Chyi Tzeng, Chih-Hua Tseng, Yeh-Long Chen
Journal: Cancer Research (2017)

Abstract Hepatocellular carcinoma (HCC) is the sixth most common cancer worldwide and the third most common cause of cancer mortality. Because of the late diagnosis, poor treatment options and high recurrence, the incidence still nearly equals to the mortality rate. Therefore, the discovery of novel therapeutic agents and/or drug combination strategies is urgently needed. Glycine N-methyltransferase (GNMT) is a tumor suppressor gene for HCC. Literatures revealed that the expression of GNMT is significantly down-regulated in HCC patients. Therefore, discovery of small molecule compounds that are able to enhance GNMT expression will have important implications for the treatment of HCC. Recently, we have identified a small molecule, 2-acetylpyridine-[N-(3-hydroxy-2-naphthoyl)]hydrazone (1), as a hit from a collective drug library containing more than 20,000 compounds using a GNMT gene expression-oriented screen platform. Preliminary results indicated that compound 1 is capable of inducing GNMT expression strongly with 7.57 folds to control in 2.5 micromole. In order to discover novel lead compounds based on the initial hit, we have synthesized more than 100 analogs of compound 1 and evaluated for their effects on GNMT promoter activity. Results indicated certain newly synthesized compounds are more active than compound 1. A comprehensive Structure-activity relationships (SAR) study will be presented. Citation Format: Cherng-Chyi Tzeng, Chih-Hua Tseng, Yeh-Long Chen. Discovery of 2-acetylpyridine-[N-(3-hydroxy-2-naphthoyl)]hydrazone analogs as glycine N-methyltransferase (GNMT) inducers for the treatment of hepatocellular carcinoma (HCC). [abstract]. In: Proceedings of the AACR Special Conference on Translational Control of Cancer: A New Frontier in Cancer Biology and Therapy; 2016 Oct 27-30; San Francisco, CA. Philadelphia (PA): AACR; Cancer Res 2017;77(6 Suppl):Abstract nr B28.
“Moxifloxacin<i>versus</i>amoxicillin/clavulanic acid in outpatient acute exacerbations of COPD: MAESTRAL results”. Robert Wilson, Antonio Anzueto, Marc Miravitlles, Pierre Arvis, Jeff Alder, Daniel Haverstock, Mila Trajanovic and Sanjay Sethi.<i>Eur Respir J</i>2012; 40: 17–27.
Authors: Katherine Floyd, Raymond Hutubessy, Kai Kliiman, Rosella Centis, Nina Khurieva, Wieslaw Jakubowiak, Manfred Danilovits, Genadi Peremitin, Salmaan Keshavjee, Giovanni Battista, Robert Wilson, Antonio Anzueto, Marc Miravitlles, Pierre Arvis, Jeff Alder, Daniel Haverstock, Mila Trajanovic, Jordi Roig, Yves Sibille, Eamonn Shanahan, Fernando De Benedetto, Nadeem Rizvi
Journal: European Respiratory Journal (2012)
Combination drug therapy allows synergistic therapeutic dose reduction in NASH: a case study of elafibranor (GFT505) and an FXR agonist combination in a model of severe NASH
Authors: V. Ratziu, S. Harrison, B. Noel, G. Rigou, N. Degallaix, V. Daix, C. Bélanger, A. Roudot, S. Megnien, D. Hum, B. Staels, R. Walczak, A. Sanyal
Journal: Journal of Hepatology (2017)
Risk factors of early emergent hospital readmission and 6-month mortality in patients with cirrhosis after a recovery from bacterial or fungal infection
Authors: F. Morando, S. Piano, S. Rosi, M. Stanco, C. Pilutti, E. Vettore, A. Romano, S. Fasolato, M. Tonon, A. Brocca, A. Sticca, P. Angeli
Journal: Journal of Hepatology (2017)
SPECIAL DEPARTMENTS
Authors: Jean-Pierre Pignon Michel Ducreux, Philippe Rougier, Charles Erlichman
Journal: Journal of Clinical Oncology (2000)

Article Tools SPECIAL DEPARTMENTS Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2000.18.1.235 Journal of Clinical Oncology - published online before print September 21, 2016 PMID: 10623717 Jean-Pierre Pignon Michel DucreuxxJean-Pierre Pignon Michel DucreuxSearch for articles by this author , Philippe RougierxPhilippe RougierSearch for articles by this author Charles ErlichmanxCharles ErlichmanSearch for articles by this author Show More Institut Gustave-Roussy VillejuifFranceHôpital Ambroise-Paré BoulogneFranceOn behalf of the IMPACT B2 Investigators Mayo Clinic RochesterMN https://doi.org/10.1200/JCO.2000.18.1.235 First Page Full Text PDF Figures and Tables © 2000 by American Society of Clinical OncologyjcoJ Clin OncolJournal of Clinical OncologyJCO0732-183X1527-7755American Society of Clinical OncologyResponse01012000In Reply:Pignon et al suggest that comparing the efficacy in stage II and III patients would have increased the power of our study. I refer them to the publication in the Lancet in 1995,1 in which a complete analysis of the total population was undertaken. In this publication, there was a statistically significant difference between the total populations treated with fluorouracil/leucovorin versus the controls and in the subset of stage III patients. At the time we did that analysis, there were insufficient events to allow an analysis of the stage II patients. The recent publication2 in the Journal of Clinical Oncology reflects the analysis when sufficient events had occurred, such that an analysis was appropriate.We could have updated the analysis for the whole population and then done a separate analysis for the stage II and III patients. However, this exercise would not have increased our power to address the question of whether fluorouracil and leucovorin had any benefit in patients with stage II colon cancer. The only way we can potentially increase the power of this study is to undertake another analysis with longer follow-up of the stage II subset. As far as the publication of the meta-analysis performed by the Colorectal Cancer Collaborative Group is concerned, it is not clear whether the question will be settled by such an analysis if there are multiple treatment regimens in which the chemotherapy is being used, which would make it more difficult to sort out whether fluorouracil/leucovorin, specifically, is useful in stage II colon cancer.3. The IMPACT Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. Lancet 345::939,1995-944, Crossref, Medline, Google Scholar3. International Multicentre Pooled Analysis of B2 Colon Cancer Treatment (IMPACT B2) Investigators: Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. J Clin Oncol 17::1356,1999-1363, Link, Google Scholar
Dysbiosis of the gut microbiota and increased gut permeability characterize secondary sclerosing cholangitis in critically ill patients (SSC-CIP)
Authors: A. Blesl, A. Horvath, C. Jüngst, B. Leber, B. Schmerboeck, M. Tawdrous, P. Stiegler, F. Rainer, W. Spindelboeck, P. Fickert, F. Lammert, M. Reichert, V. Stadlbauer
Journal: Journal of Hepatology (2017)
CD34/EPO-R Double Positive MDS Cells Produce Erythroferrone in Response to Erythropoietin
Authors: Shogo Miura, Masayoshi Kobune, Soushi Ibata, Masahiro Yoshida, Satoshi Iyama, Tsutomu Sato, Kazuyuki Murase, Kohichi Takada, Kaoru Ono, Akari Hashimoto, Ayumi Tatekoshi, Yusuke Kamihara, Yusuke Sugama, Wataru Jomen, Shohei Kikuchi, Hiroshi Ikeda, Hiroto Horiguchi, Yutaka Kawano, Koji Miyanishi, Hiroyuki Kuroda, Masahiro Maeda, Junji Kato
Journal: Blood (2016)
The absence of OCT1 at the plasma membrane of tumor cells is associated with a worse response of hepatocellular carcinoma to sorafenib
Authors: A. Geier, R. Al-Abdulla, R. Macias, D. Bettinger, J. Weiss, H. Bantel, D. Jahn, M. Ascensio, M. Alonso-Pena, F. Al-Aqil, J. Marin
Journal: Journal of Hepatology (2017)
The point of care 13C-Methacetin Breath Test predicts risk of long-term liver-related death or transplantation in patients with chronic liver disease: a sensitive, noninvasive monitoring tool in clinical hepatology
Authors: M.L. Shiffman, M.S. Siddiqui, T. Khoury, S.C. Gordon, G. Lalazar, A. Reuben, A.J. McCullough, K.R. Reddy, F. Poordad, Z.M. Younossi, J.M. Vierling, A. Fich, E. Zuckerman, Y. Ilan, A.J. Sanyal
Journal: Journal of Hepatology (2017)
Leptin receptor antagonism of iNKT cell function: a novel strategy to combat multiple myeloma
Authors: M Favreau, E Menu, D Gaublomme, K Vanderkerken, S Faict, K Maes, E De Bruyne, S Govindarajan, M Drennan, S Van Calenbergh, X Leleu, L Zabeau, J Tavernier, K Venken, D Elewaut
Journal: Leukemia (2017)
A Path Beyond Advocacy to Improve Mental Health Services for Children and Families
Authors: Michael Jellinek
Journal: JAMA Pediatrics (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Pediatrics HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Pediatrics journal
Long-Term Treatment with Imatinib Is Associated with Decreased Estimated Glomerular Filtration Rate and Hemoglobin Level in Patients with Chronic Myelogenous Leukemia
Authors: Masatoshi Sakurai, Takehiko Mori, Daiki Karigane, Hidenori Kasahara, Keiichi Tozawa, Eri Matsuki, Taku Kikuchi, Jun Kato, Takayuki Shimizu, Shinichiro Okamoto
Journal: Blood (2016)
A Prostate Cancer “ Nimbosus ”: Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies
Authors: Melvin L.K. Chua, Winnie Lo, Melania Pintilie, Jure Murgic, Emilie Lalonde, Vinayak Bhandari, Osman Mahamud, Anuradha Gopalan, Charlotte F. Kweldam, Geert J.L.H. van Leenders, Esther I. Verhoef, Agnes Marije Hoogland, Julie Livingstone, Alejandro Berlin, Alan Dal Pra, Alice Meng, Junyan Zhang, Michèle Orain, Valérie Picard, Hélène Hovington, Alain Bergeron, Louis Lacombe, Yves Fradet, Bernard Têtu, Victor E. Reuter, Neil Fleshner, Michael Fraser, Paul C. Boutros, Theodorus H. van der Kwast, Robert G. Bristow
Journal: European Urology (2017)
Abstract #4321: Structural and functional molecular imaging for microscopy: new capabilities
Authors: Richard Levenson, Peter Miller, Clifford Hoyt
Journal: Cancer Research (2009)

AACR Annual Meeting-- Apr 18-22, 2009; Denver, CO

We present a novel multispectral and polarization-based camera system, along with powerful but accessible image analysis techniques, that can acquire and quantitatively assess structural and multiplexed molecular information for purposes of automated multiplexed tissue phenotyping and patient stratification. Molecular imaging at the microscopic scale uses such techniques as immunohistochemistry, immunofluorescence and various in-situ hybridization techniques to detect the presence and abundance of a wide variety of molecules, with remarkable specificity. With the advent of multispectral imaging techniques, it is possible to image as many as 7 or more molecular signals in a single specimen. However, these procedures often present their highly specific results in a scanty structural context. That is to say, the background architectural information is often absent, as with IF or FISH accompanied only by a nuclear counterstain such as DAPI, or with limited details, as in IHC with a hematoxylin counterstain that inadequately highlights cytoplasmic and stromal details. We describe a novel birefringence imaging system that can detect structural molecules such as collagen with high sensitivity, in conventional histological slides. The samples can be unstained, stained with hematoxylin and eosin (HE moreover, the quality of the optically detected collagen images is superior to that available with such conventional stains, and is similar to images achievable with considerably more complex and expensive laser-based second-harmonic generation imaging systems. The birefringence technique provides quantitatively accurate images reflecting the abundance and orientation of individual collagen bundles. Moreover, this capability has been combined, in a single instrument, with multispectral imaging optics, to provide completely new imaging options that merge structural and molecular information; the resulting multimodal images can be layered in multiplane image stacks with control over the display of individual signals. The system can be attached to any conventional microscope via a standard C-mount connection. Automated image segmentation providing separation of the images into different tissue classes (cancer, stroma, scar, necrosis, e.g.) is an essential part of a fully automated molecular analysis system. Adding additional structural information via a collagen image to other, molecularly specific, images can enhance the performance of image segmentation procedures, especially for fluorescence-based techniques. This new imaging system should prove useful in a variety of contexts, including the study of cancer interactions with host stroma, fibrosis in a variety of pathologies including hepatic and renal disease, dermatology, to name just a few potential application areas.

Citation Information: In: Proc Am Assoc Cancer Res; 2009 Apr 18-22; Denver, CO. Philadelphia (PA): AACR; 2009. Abstract nr 4321.
Absence of mutations in the HBsAg “a” determinant during REP 2139 therapy validates serum HBsAg reductions observed in the REP 102 protocol
Authors: Z. Usman, H. Mijočević, H. Karimzadeh, M. Al-Mahtab, M. Bazinet, D. Frishman, A. Vaillant, M. Roggendorf
Journal: Journal of Hepatology (2017)
Predictors of persistence of clinical significant portal hypertension in patients with HCV liver cirrhosis following 3D therapy and SVR
Authors: M.C.S. Iacob, L. Gheorghe, C. Cijevschi, A. Trifan, C. Stanciu, C. Mihai, I. Sporea, R. Sirli, M. Curescu, M. Diculescu, L. Alexandrescu, L. Sandulescu, A. Goldis, C. Brisc, I. Simionov, R. Vadan, I. Pirvulescu, I. Rogoveanu, C. Pietrareanu, A. Seicean, R. Iacob, C. Gheorghe
Journal: Journal of Hepatology (2017)